サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1388224

潜在性結核診断の世界市場：アッセイ別、危険因子別、ラボ/場所別予測 - エグゼクティブコンサルタントガイド付き（2024年～2028年）

Latent TB Diagnostics Global Markets by Assay, by Risk Factor, and by Lab/Place. With Executive and Consultant Guides and Market Analysis and Forecasts 2024 - 2028
出版日: | 発行: Howe Sound Research | ページ情報: 英文 316 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
潜在性結核診断の世界市場：アッセイ別、危険因子別、ラボ/場所別予測 - エグゼクティブコンサルタントガイド付き（2024年～2028年）
出版日: 2023年10月10日
発行: Howe Sound Research
ページ情報: 英文 316 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートは、世界の潜在性結核診断市場について調査し、市場の概要とともに、アッセイ別、危険因子別、ラボ/場所別動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 市場ガイド

第2章 イントロダクションと市場の定義

  • 結核診断の概要
  • 市場の定義
  • 調査手法
  • ヘルスケアとIVD産業

第3章 結核と現在の科学

  • 結核とは何か
    • 原因
    • 病因
    • 予防
    • 治療
  • 診断
    • 活動性結核
    • 潜在性結核
  • 有病率
    • 結核罹患率に対する新型コロナウイルスの影響

第4章 業界の概要

  • 市場参入組織
    • 学術研究機関
    • 診断試験開発者
    • 医薬品・試薬サプライヤー
    • 独立系臨床検査室
    • 公共の国立/地域研究所
    • 病院検査室
    • 臨床検査室
    • 監査機関
    • 認証機関

第5章 市場動向

  • 成長促進要因
  • 成長抑制要因
  • 診断技術開発

第6章 結核の診断- 最近の開発

第7章 主要企業の概要

  • AID GmbH
  • Beijing Wantai
  • bioMérieux Diagnostics
  • Boditech Med, Inc
  • Endo International
  • Erythra
  • Generium
  • Glory Biotechnologies Corp.
  • Lionex Diagnostics & Therapeutics GmbH
  • Oxford Immunotec（Perkin Elmer）
  • Perkin Elmer
  • Qiagen
  • R-Biopharm AG
  • Sanofi
  • SD Biosensor
  • Serum Institute of India
  • Statens Serum Institut
  • Zhifei Longcom

第8章 世界の潜在性結核診断市場の概要

  • 国別市場概要
  • アッセイ別市場概要
  • 危険因子別市場概要
  • ラボ別市場概要

第9章 潜在性結核診断市場、アッセイ別

  • 潜在性結核診断-TST
  • 潜在性結核診断-IGRA
  • 潜在性結核診断-TBST
  • 潜在性結核診断- その他

第10章 世界の潜在性結核診断市場- 危険因子別

  • 潜在性結核の診断-HIV
  • 潜在性結核の診断- 小児
  • 潜在性結核の診断- 糖尿病
  • 潜在性結核の診断- 移民
  • 潜在的な結核の診断- その他

第11章 世界の潜在性結核診断市場- ラボ/場所別

  • 病院検査室
  • 外来検査室
  • ポイントオブケア
  • その他の場所

第12章 付録

図表

Table of Tables

  • Table 1: TST vs IGRA
  • Table 2: Market Players by Type
  • Table 3: Five Factors Driving Growth
  • Table 4: Three Factors Limiting Growth
  • Table 5: Global Latent TB Diagnostics Market by Country/Region
  • Table 6: Global Market by Assay
  • Table 7: Global Market by Risk Factor
  • Table 8: Global Market by Lab
  • Table 9: Latent TB Diagnostic TST by Country
  • Table 10: Latent TB Diagnostic IGRA by Country
  • Table 11: Latent TB Diagnostic TBST by Country
  • Table 12: Latent TB Diagnostic Other by Country
  • Table 13: Latent TB Diagnostic HIV by Country
  • Table 14: Latent TB Diagnostic Pediatric by Country
  • Table 15: Latent TB Diagnostic Diabetes by Country
  • Table 16: Latent TB Diagnostic Immigration by Country
  • Table 17: Latent TB Diagnostic Other Risk Factor by Country
  • Table 18: Latent TB Diagnostic Hospital Lab by Country
  • Table 19: Latent TB Diagnostic Outpatient Lab by Country
  • Table 20: Latent TB Diagnostic Point of Care by Country
  • Table 21: Latent TB Diagnostic Other Place by Country
  • Table 22: Clinical Lab Fee Schedule

Table of Figures

  • Figure 1: Global Prevalence of TB - 2019
  • Figure 2: Global Healthcare Spending Map
  • Figure 3: The Lab Test Pie - Wholesale and Retail
  • Figure 4: Percentage of World Population Over 65
  • Figure 5: Growth in Health Care Spending Developing World
  • Figure 6: Comparing The New Diagnostics and Traditional Testing
  • Figure 7: Growth rates of Latent TB Diagnostics
  • Figure 8: Global Market Share Chart
  • Figure 9: Latent TB Diagnostics Market Segment Shift Base vs Final year
  • Figure 10: Latent TB Diagnostics Market by Assay Base Year
  • Figure 11: Latent TB Diagnostics Market by Assay Final Year
  • Figure 12: Latent TB Diagnostics Market Segment Shift Base vs Final year
  • Figure 13: Latent TB Diagnostics Market by Risk Factor Base Year
  • Figure 14: Latent TB Diagnostics Market by Risk Factor Final Year
  • Figure 15: Latent TB Diagnostics Market Segment Shift Base vs Final year
  • Figure 16: Latent TB Diagnostics Market by Lab Base Year
  • Figure 17: Latent TB Diagnostics Market by Lab Final Year
  • Figure 18: Latent TB Diagnostic TST Growth
  • Figure 19: LATENT TB Diagnostics Syndromic POC Panel Growth
  • Figure 20: Latent TB Diagnostic TBST Growth
  • Figure 21: Latent TB Diagnostic Other Growth
  • Figure 22: Latent TB Diagnostic HIV Growth
  • Figure 23: LATENT TB Diagnostics Pediatric
  • Figure 24: Latent TB Diagnostic Diabetes Growth
  • Figure 25: Latent TB Diagnostic Immigration Growth
  • Figure 26: Latent TB Diagnostic Other Risk Factor Growth
  • Figure 27: Latent TB Diagnostic Hospital Lab Growth
  • Figure 28: Latent TB Diagnostic Outpatient Lab Growth
  • Figure 29: LATENT TB Diagnostics Point of Care
  • Figure 30: LATENT TB Diagnostics Other Place
目次

OVERVIEW:

Your report is provided on a 12-month subscription basis from the date you receive your first report. You will receive 2 or more updated versions of the complete report during the 12 months. At least one of these updates will provide forecasts based on next year's data.

Latent TB Diagnostics was the province of a few established companies producing a commodity product. No longer. New technologies. New niche markets.

TB Diagnostics is growing, and in some segments the growth is dramatic. Find out who the new leaders are and what areas are most lucrative. What are the basics of competition?

The report forecasts the market size out five years. Some players have already made their mark but disruptive diagnostic technology could change the playing field. Learn about this market including the issues and outlooks.

All report data is available in Excel format on request.

Make investment decisions and valuations with confidence using the latest data.

ABOUT THE LEAD AUTHOR:

Mr. Greg Powell, B.SC., M.B.A is the President of Howe Sound Research. He is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell's education includes:

  • B.Sc. (Chemistry) University of BC
  • M.B.A. (Finance and Policy) University of BC
  • Market Research Seminar - Burke Institute
  • Finance for Senior Executives - Harvard Business School

Table of Contents

1. Market Guides

  • 1.1. Situation Analysis
  • 1.2. Guide for Executives and Marketing Staff
  • 1.3. Guide for Investment Analysts and Management Consultants

2. Introduction and Market Definition

  • 2.1. An Overview of TB Diagnostics
    • 2.1.1. The New Antigen Based TBST
  • 2.2. Market Definition
    • 2.2.1. Market Size
    • 2.2.2. Currency
    • 2.2.3. Years
    • 2.2.4. Limitations
  • 2.3. Methodology
    • 2.3.1. Methodology
    • 2.3.2. Sources
    • 2.3.3. Authors
  • 2.4. Healthcare and the IVD Industry
    • 2.4.1. Global Healthcare Spending
    • 2.4.2. Spending on Diagnostics
    • 2.4.3. Important Role of Insurance for Diagnostics

3. Tuberculosis-Current Science

  • 3.1. What is Tuberculosis?
    • 3.1.1. Causes
    • 3.1.2. Pathogenesis
    • 3.1.3. Prevention
    • 3.1.4. Treatment
  • 3.2. Diagnosis
    • 3.2.1. Active TB
    • 3.2.2. Latent TB
  • 3.3. Prevalence
    • 3.3.1. Impact of COVID on TB Prevalence

4. Industry Overview

  • 4.1. Players in a Dynamic Market
    • 4.1.1. Academic Research Lab
    • 4.1.2. Diagnostic Test Developer
    • 4.1.3. Pharmaceutical/Reagent Supplier
    • 4.1.4. Independent Testing Lab
    • 4.1.5. Public National/regional lab
    • 4.1.6. Hospital lab
    • 4.1.7. Physician Lab
    • 4.1.8. Audit Body
    • 4.1.9. Certification Body

5. Market Trends

  • 5.1. Factors Driving Growth
    • 5.1.1. Increasing Prevalence
    • 5.1.2. Increasing Diagnostic Options
    • 5.1.3. The Aging World
    • 5.1.4. Increased Health Care Spending
  • 5.2. Factors Limiting Growth
    • 5.2.1. The Cost Curve Shrinks the Market
    • 5.2.2. The Diagnostics Dillemma
    • 5.2.3. Adoption Lag and Cost Control
  • 5.3. Diagnostic Technology Development
    • 5.3.1. The Multiplex Opportunity
    • 5.3.2. Shifting Role of Physicians in Diagnosis
    • 5.3.3. Diagnostics Moves Out of the Lab
    • 5.3.4. Rapid Testing Changing Medical Practice
    • 5.3.5. The Next Five Years

6. TB Diagnostics - Recent Developments

  • 6.1. Recent Developments-Importance and How to Use This Section
    • 6.1.1. Importance of These Developments
    • 6.1.2. How to Use This Section
  • 6.2. New skin test for latent TB diagnostics
  • 6.3. Latent TB Infection Screening Recommended
  • 6.4. QIAGEN's QuantiFERON-TB Gold Plus gains new CE-marking
  • 6.5. PerkinElmer Hopes to Gain Market Share against Qiagen
  • 6.6. PBD Biotech to Develop TB Blood Test
  • 6.7. WHO Expands Assessment for TB MDx Developers
  • 6.8. Cepheid Omni POC System Falls Off Radar
  • 6.9. Non-Sputum CRISPR-Based TB Test Shows High Sensitivity
  • 6.10. NGeneBio Gets CE Mark for NGS-Based TB Assay
  • 6.11. MDx TB Assay From PBD Biotech Shows Promise
  • 6.12. Minute Molecular Dx to Launch Rapid PCR Test
  • 6.13. Qiagen Next-Gen TB Test Gains Chinese Approval
  • 6.14. FIND Invests $21M to Launch POC MDx Platforms
  • 6.15. Qiagen, DiaSorin Obtain FDA Approval for Latent TB Test
  • 6.16. Oxford Immunotec to Automate Latent TB Test
  • 6.17. LumiraDx Eyes Test Menu Expansion
  • 6.18. BioMérieux Targeting Hospitals With Desktop Latent TB Test

7. Profiles of Key Companies

  • 7.1. AID GmbH
  • 7.2. Beijing Wantai
  • 7.3. bioMérieux Diagnostics
  • 7.4. Boditech Med, Inc
  • 7.5. Endo International
  • 7.6. Erythra
  • 7.7. Generium
  • 7.8. Glory Biotechnologies Corp.
  • 7.9. Lionex Diagnostics & Therapeutics GmbH
  • 7.10. Oxford Immunotec (Perkin Elmer)
  • 7.11. Perkin Elmer
  • 7.12. Qiagen
  • 7.13. R-Biopharm AG
  • 7.14. Sanofi
  • 7.15. SD Biosensor
  • 7.16. Serum Institute of India
  • 7.17. Statens Serum Institut
  • 7.18. Zhifei Longcom

8. Latent TB Global Diagnostic Markets Overview

  • 8.1. Latent TB Diagnostics-Global Market Overview by Country
    • 8.1.1. Table-Global Market by Country
    • 8.1.2. Chart - Global Market by Country
  • 8.2. Global Latent TB Diagnostics Markets Overview by Assay
    • 8.2.1. Table-Global Market by Assay
    • 8.2.2. Chart-Global Market by Assay-Segments Growth
    • 8.2.3. Chart-Global Market by Assay-Share by Year
    • 8.2.4. Chart-Global Market by Assay
    • 8.2.5. Chart-Global Market by Assay-Base Year
    • 8.2.6. Chart-Global Market by Assay-Final Year
  • 8.3. Global Latent TB Diagnostics Markets Overview by Risk Factor
    • 8.3.1. Table-Global Market by Risk Factor
    • 8.3.2. Chart-Global Market by Risk Factor-Segments Growth
    • 8.3.3. Chart-Global Market by Risk Factor-Share by Year
    • 8.3.4. Chart-Global Market by Risk Factor
    • 8.3.5. Chart-Global Market by Risk Factor-Base Year
    • 8.3.6. Chart-Global Market by Risk Factor-Final Year
  • 8.4. Global Latent TB Diagnostics Markets Overview by Lab
    • 8.4.1. Table-Global Market by Lab
    • 8.4.2. Chart-Global Market by Lab-Segments Growth
    • 8.4.3. Chart-Global Market by Lab-Share by Year
    • 8.4.4. Chart-Global Market by Lab
    • 8.4.5. Chart-Global Market by Lab-Base Year
    • 8.4.6. Chart-Global Market by Lab-Final Year

9. Latent TB Diagnostic Market-by Assay

  • 9.1. Latent TB Diagnostic - TST
    • 9.1.1. Table Latent TB Diagnostic TST-by Country
    • 9.1.2. Chart - Latent TB Diagnostic TST Growth
  • 9.2. Latent TB Diagnostic - IGRA
    • 9.2.1. Table Latent TB Diagnostic IGRA-by Country
    • 9.2.2. Chart - Latent TB Diagnostic IGRA Growth
  • 9.3. Latent TB Diagnostic-TBST
    • 9.3.1. Table Latent TB Diagnostic TBST-by Country
    • 9.3.2. Chart - Latent TB Diagnostic-TBST Growth
  • 9.4. Latent TB Diagnostic -Other
    • 9.4.1. Table Latent TB Diagnostic Other-by Country
    • 9.4.2. Chart - Latent TB Diagnostic-Other Growth

10. Global Latent TB Diagnostics Markets-By Risk Factor

  • 10.1. Latent TB Diagnostic - HIV
    • 10.1.1. Table Latent TB Diagnostic HIV-by Country
    • 10.1.2. Chart - Latent TB Diagnostic HIV Growth
  • 10.2. Latent TB Diagnostic-Pediatric
    • 10.2.1. Table Latent TB Diagnostic Pediatric- by Country
    • 10.2.2. Chart - Latent TB Diagnostic Pediatric
  • 10.3. Latent TB Diagnostic-Diabetes
    • 10.3.1. Table Latent TB Diagnostic Diabetes-by Country
    • 10.3.2. Chart - Latent TB Diagnostic-Diabetes Growth
  • 10.4. Latent TB Diagnostic-Immigration
    • 10.4.1. Table Latent TB Diagnostic Immigration-by Country
    • 10.4.2. Chart - Latent TB Diagnostic-Immigration Growth
  • 10.5. Latent TB Diagnostic-Other Risk Factor
    • 10.5.1. Table Latent TB Diagnostic Other Risk Factor-by Country
    • 10.5.2. Chart - Latent TB Diagnostic-Other Risk Factor Growth

11. Global Latent TB Diagnostics Markets-By Lab/Place

  • 11.1. Latent TB Diagnostic-Hospital Lab
    • 11.1.1. Table Latent TB Diagnostic Hospital Lab-by Country
    • 11.1.2. Chart - Latent TB Diagnostic Hospital Lab Growth
  • 11.2. Latent TB Diagnostic-Outpatient Lab
    • 11.2.1. Table Latent TB Diagnostic Outpatient Lab-by Country
    • 11.2.2. Chart - Latent TB Diagnostic Outpatient Lab Growth
  • 11.3. Latent TB Diagnostic-Point of Care
    • 11.3.1. Table Latent TB Diagnostic Point of Care-by Country
    • 11.3.2. Chart - Latent TB Diagnostic Point of Care
  • 11.4. Latent TB Diagnostic-Other Place
    • 11.4.1. Table Latent TB Diagnostic Other Place-by Country
    • 11.4.2. Chart - Latent TB Diagnostic Other Place

12. Appendices

  • 12.1. United States Medicare System: Clinical Laboratory Fees Schedule